Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

54.08
+0.39000.73%
Post-market: 54.080.00000.00%19:44 EDT
Volume:1.95M
Turnover:105.64M
Market Cap:13.40B
PE:17.01
High:54.68
Open:53.74
Low:53.70
Close:53.69
52wk High:57.57
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:0.93
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.27
PE(LYR):19.45

Loading ...

Exelixis is Maintained at Hold by Truist Securities

Dow Jones
·
Jul 07

RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating

MT Newswires Live
·
Jul 07

Is Exelixis (EXEL) Undervalued Or Already Priced In On Its Oncology Growth Story?

Simply Wall St.
·
Jul 05

Sector Update: Healthcare Stocks Gain Thursday Afternoon

MT Newswires Live
·
Jul 03

Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says

MT Newswires Live
·
Jul 03

UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating

MT Newswires Live
·
Jul 02

Exelixis Inc : UBS Raises Target Price to $52 from $43

THOMSON REUTERS
·
Jul 02

Exelixis is Maintained at Neutral by UBS

Dow Jones
·
Jul 02

Exelixis Price Target Maintained with a $56.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 02

Apollo, Exelixis, Devon, Qualcomm, Oklo Trending With Analysts

TIPRANKS
·
Jun 27

Is Exelixis (EXEL) Fully Valued On Its STELLAR 303 Trial Update?

Simply Wall St.
·
Jun 27

Exelixis Cut to Hold from Buy by Truist Securities

Dow Jones
·
Jun 25

Exelixis Inc : Truist Securities Cuts to Hold from Buy; Raises Target Price to $54 from $51

THOMSON REUTERS
·
Jun 25

Exelixis assumed with Hold from Buy at Truist

TIPRANKS
·
Jun 25

U.S. Research Roundup-caseys General Stores, Micron Technology, SAP

Reuters
·
Jun 25

Exelixis is Maintained at Market Outperform by Citizens

Dow Jones
·
Jun 24

Exelixis Colorectal Cancer Data Underwhelms: Gerberry Maintains Sell/Underperform with Price Target Below Current Share Price

TIPRANKS
·
Jun 23

Exelixis announces results from final analysis of phase 3 STELLAR-303 trial

TIPRANKS
·
Jun 22

Exelixis says STELLAR-303 trial misses statistical significance for survival in metastatic colorectal cancer non-liver subgroup

Reuters
·
Jun 22

Exelixis Provides Update on the Phase 3 Stellar-303 Trial Evaluating Zanzalintinib in Combination With an Immune Checkpoint Inhibitor in Patients With Metastatic Colorectal Cancer

THOMSON REUTERS
·
Jun 22